Veracyte, Inc. (VCYT)

19,55 +0,07 (+0,36%) In data: 02:07PM EDT. Mercato aperto.

Veracyte, Inc.

6000 Shoreline Court
Suite 300
South San Francisco, CA 94080
United States
650 243 6300
https://www.veracyte.com

Settore/i: Healthcare
Settore: Diagnostics & Research
Impiegati a tempo pieno: 815

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Mr. Marc A. Stapley	CEO & Director	1,25M	N/D	1970
Ms. Annie McGuire	Executive VP, General Counsel & Chief People Officer	633,65k	N/D	1981
Mr. Jonathan Wygant	VP & Chief Accounting Officer	N/D	N/D	1971
Mr. Steven French	Senior VP & Chief Information Officer	N/D	N/D	N/D
Dr. Phillip G. Febbo M.D.	Chief Scientific & Medical Officer	N/D	N/D	1966
Ms. Karen Possemato	Senior Vice President of Corporate Marketing, Communications & Commercial Operations	N/D	N/D	N/D
Mr. Robert Brainin	Executive VP & Chief Business Officer	N/D	N/D	1971
Dr. John Leite Ph.D.	Chief Commercial Officer for CLIA Business	N/D	N/D	N/D
Ms. Corinne Danan	Senior Vice President	N/D	N/D	N/D
Ms. Beverly Jane Alley CPA	VP & Corporate Controller	398,01k	N/D	1963

Gli importi risalgono al giorno 31 dicembre 2022 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Nasal Swab Test for lung cancer diagnosis; and Envisia Genomic Classifier for diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis. It is also developing Envisia Classifier, the nCounter analysis system; and LymphMark for lymphoma subtyping test. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.

Governance aziendale

L'ISS Governance QualityScore di Veracyte, Inc. al 1 aprile 2024 è 4. I criteri di valutazione fondamentali sono revisione: 5; Consiglio di Amministrazione: 2; diritti degli azionisti: 4; retribuzione: 7.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.